Cytori to Begin Stem Cell Trial for Heart Disease
Cytori Therapeutics received approvals to initiate a clinical trial in Spain to investigate the use of adipose-derived stem and regenerative cells for the treatment of cardiovascular disease. The cells will be obtained at the bedside from the patients' own adipose (fat) tissue and made available in real-time using Cytori's Celution' stem and regenerative cell processing system. Patient enrollment will begin imminently.
Cytori's trial, designated as the 'PRECISE' study, will primarily evaluate safety and feasibility in 36 patients with chronic ischemia, a severe form of coronary artery disease. The Company's Celution' stem and regenerative cell processing system will extract and concentrate a patient's cells in the catheterization suite so they are available for the physician to re-inject into damaged heart muscle in about an hour. A variety of clinical functional and imaging endpoints will be assessed in the study. The outcomes of the study will be evaluated after a six month follow up.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.